Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Labo Euromedis's shares outstanding for the quarter that ended in Dec. 2025 was 2.86 Mil.
Labo Euromedis's quarterly shares outstanding
increased
from Jun. 2025 (2.84 Mil) to Dec. 2025 (2.86 Mil).
It means Labo Euromedisissued new shares from Jun. 2025 to Dec. 2025 .
Labo Euromedis's annual shares outstanding
increased
from Dec. 2024 (2.84 Mil) to Dec. 2025 (2.86 Mil).
It means Labo Euromedisissued new shares from Dec. 2024 to Dec. 2025 .
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Labo Euromedis Shares Outstanding (EOP) Related Terms
Labo Euromedis Shares Outstanding (EOP) Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:61R vs MCK, CAH, COR: Shares Outstanding (EOP) Comparison
For the Medical Distribution subindustry, Labo Euromedis's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Shares Outstanding (EOP) vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 2.86 Mil mean?
Labo Euromedis (STU:61R) has a Shares Outstanding (EOP) of 2.86 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Labo Euromedis and its competitors.
Is Labo Euromedis' Shares Outstanding (EOP) too high?
Labo Euromedis' current Shares Outstanding (EOP) is 2.86 Mil. Overall, Labo Euromedis has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Shares Outstanding (EOP) compare to MCK and CAH?
Labo Euromedis' Shares Outstanding (EOP) of 2.86 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Distribution company?
A good Shares Outstanding (EOP) depends on the Medical Distribution industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Labo Euromedis and its competitors. Labo Euromedis's current Shares Outstanding (EOP) is 2.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (STU:61R) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.39, compared to a current price of €4.88 — trading 11.2% above its estimated fair value. The current Shares Outstanding (EOP) is 2.86 Mil. Labo Euromedis' overall GF Score™ is 68/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Labo Euromedis (STU:61R), the current Shares Outstanding (EOP) is 2.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (STU:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.88 is trading 11.2% above its estimated GF Value™ of €4.39.
GuruFocus considers Labo Euromedis to be Modestly Overvalued.
Key valuation signals for STU:61R:
Shares Outstanding (EOP): 2.86 Mil
GF Value™: €4.39 vs. price of €4.88 (11.2% above fair value)
No single metric tells the full story. See the STU:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
68GF Score
Get the complete analysis for STU:61R
Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:61R has been successfully added to your 
